The Lancet Gastroenterology & Hepatology in conversation with

<p>Hugh Thomas, Deputy Editor at <em>The Lancet Gastroenterology & Hepatology</em>, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy.<br><br></p><p>A monthly audio companion to the journal, this podcast covers a broad range of topics, from predicting clinical outcomes in NAFLD to immunosuppressant withdrawal in patients with Crohn’s disease, the primary antibiotic resistance of Helicobacter pylori to surgical versus non-surgical management of malignant bowel obstruction, and more.</p>

Sanna Nybacka and Magnus Simrén on a trial of low FODMAP diets versus low carbohydrate diets in IBS

Sanna Nybacka and Magnus Simrén (University of Gothenburg) discuss the CARIBS randomised controlled trial of a low FODMAP diet versus a low-carbohydrate diet versus pharmacological treatment in IBS.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00045-1/fulltext?dgcid=buzzsprout_tlv_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelan...

05-17
23:16

Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease

Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/comp...

05-07
19:55

Yusuke Shimakawa on a simple score for hepatitis B treatment eligibility in Africa

Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00449-1?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://...

04-22
20:54

Mads Israelsen on validating the new steatotic liver disease nomenclature in people with excessive alcohol intake

Mads Israelsen (Odense University Hospital) discusses a study to validate the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00443-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttp...

03-12
16:39

Louise Dye on the role of expectancy and gluten in non-coeliac gluten sensitivity

Louise Dye (University of Leeds) discusses a trial exploring the role of expectancy and gluten ingestion on symptoms in people with non-coeliac gluten sensitivity.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00317-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.c...

03-01
23:19

Tzu-Chan Hong on the primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region

Tzu-Chan Hong (National Taiwan University Cancer Centre) discusses a systematic review and meta-analysis on primary antibiotic resistance of Helicobacter pylori between 1990 and 2022 in the Asia-Pacific region.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00281-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://faceboo...

12-19
14:40

Sarah Moen on metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after colectomy

Sarah Moen (Erasmus University Medical Center) discusses a retrospective cohort study examining the risk of metachronous colorectal cancer after partial or extensive colectomy in carriers of different pathogenic Lynch syndrome variants.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00228-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/the...

11-29
14:45

Anna Emilie Kann on the causes of mortality in patients with alcohol-related liver disease

Anna Emilie Kann (Zealand University Hospital, Denmark) discusses a population-based study done in Denmark exploring the causes of mortality in patients with alcohol-related liver disease.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00192-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetm...

10-12
16:19

Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction

Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00191-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps:/...

09-13
16:31

Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00145-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://t...

08-10
14:29

Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease

Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00017-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljourn...

07-12
17:41

Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis

Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00098-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on soci...

06-07
12:48

Adelina Artenie on the incidence of HIV and HCV in people who inject drugs

Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender. Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00018-3/fulltext?dgcid=buzzsprout_icw_podcast_langas_lancetContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.co...

05-10
17:15

Johan Burisch on the costs of inflammatory bowel disease in high-income settings

Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings.Read the Commission here:The cost of inflammatory bowel disease in high-income settingsContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.co...

04-12
20:00

Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease

Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.Read the full article:Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE)Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedic...

02-08
21:30

Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer

Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma. Read the full article:Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5)Continue this conversation on social!Follow us today at...h...

01-23
20:20

Dan Turner on vedolizumab in children with IBD

Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD.Read the full article:Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS)Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://yo...

01-06
14:51

Simon Baunwall on faecal microbiota transplantation for first or second Clostridioides difficile infection

Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection.Read the full article:Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT)Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps...

11-09
15:21

James Alexander on immune responses to COVID-19 vaccination in patients with IBD

James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease.Read the full article:COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP)Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagr...

10-05
13:48

Filip Knop on liraglutide for bile acid diarrhoea

Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea.Read the full article:Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trialContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttp...

09-07
15:02

Recommend Channels